Quantum BioPharma Featured in CTV Investigation on Stock Manipulation Allegations

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that CTV News' investigative program W5 is airing a three-part series examining the company and its allegations of stock market manipulation. The series, which began airing today, focuses on what W5 investigative reporter Jon Woodward describes in his article titled "Was a Canadian company's multiple sclerosis research nearly derailed by 'market manipulation'?" as central to Quantum BioPharma's $700 million lawsuit against CIBC and RBC.

The investigation highlights "stock spoofing," an illegal trading tactic that Quantum BioPharma alleges was used against the company. CEO Zeeshan Saeed expressed gratitude for W5's reporting and reiterated the company's commitment to advancing Lucid-MS, a drug candidate that has shown potential in animal studies to halt and reverse nerve-cell degradation in multiple sclerosis. The company maintains that the alleged market manipulation activities threatened to derail their important research efforts.

Quantum BioPharma's legal action represents one of the largest lawsuits of its kind in Canada, targeting two of the country's major financial institutions. The case brings attention to the broader issue of market manipulation practices and their potential impact on emerging biopharmaceutical companies developing treatments for serious medical conditions. The timing of the W5 investigation coincides with ongoing legal proceedings and raises questions about regulatory oversight in financial markets.

The company's focus on Lucid-MS as a potential treatment for multiple sclerosis adds significance to the allegations, as any disruption to research funding or stock performance could potentially delay development of what appears to be a promising therapeutic candidate. Multiple sclerosis affects millions worldwide, and treatments that can halt or reverse nerve damage represent a major advancement in neurological medicine. The full press release detailing the company's position is available at https://ibn.fm/5join.

This investigation comes at a critical time for Quantum BioPharma as it continues development of its neurodegenerative disorder portfolio. The company's allegations against major financial institutions highlight the complex relationship between capital markets and biomedical innovation, particularly for companies working on treatments for challenging conditions like multiple sclerosis. The outcome of both the legal proceedings and the W5 investigation could have broader implications for how market manipulation is addressed in the biopharmaceutical sector.